Hologic, Inc. (HOLX)
NASDAQ: HOLX · Real-Time Price · USD
57.12
-1.69 (-2.87%)
May 13, 2025, 4:00 PM - Market closed
Revenue by Product
Fiscal year is October - September.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | NaN - NaN |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 29, 2025 | Sep '24 Sep 28, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 24, 2022 | Sep '21 Sep 25, 2021 | NaN - NaN |
| Diagnostics | 1.81B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Diagnostics Growth | 3.10% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Breast Health | 1.49B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Breast Health Growth | 0.70% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| GYN Surgical | 651.90M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| GYN Surgical Growth | 4.55% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Skeletal Health | 80.50M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Skeletal Health Growth | -25.19% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Capex by Product
Fiscal year is October - September.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | NaN - NaN |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 29, 2025 | Sep '24 Sep 28, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 24, 2022 | Sep '21 Sep 25, 2021 | NaN - NaN |
| Diagnostics Capital Expenditures | 80.70M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Diagnostics Capital Expenditures Growth | 34.85% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Breast Health Capital Expenditures | 28.10M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Breast Health Capital Expenditures Growth | -44.44% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| GYN Surgical Capital Expenditures | 22.80M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| GYN Surgical Capital Expenditures Growth | 268.00% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Skeletal Health Capital Expenditures | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Skeletal Health Capital Expenditures Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is October - September.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | NaN - NaN |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 29, 2025 | Sep '24 Sep 28, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 24, 2022 | Sep '21 Sep 25, 2021 | NaN - NaN |
| Diagnostics Operating Income | 321.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Diagnostics Operating Income Growth | 452.50% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Breast Health Operating Income | 363.80M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Breast Health Operating Income Growth | 22.70% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| GYN Surgical Operating Income | 19.90M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| GYN Surgical Operating Income Growth | -88.65% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Skeletal Health Operating Income | -7.90M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Skeletal Health Operating Income Growth | -162.70% |
Log In |
Log In |
Log In |
Log In | Upgrade
|